Let's talk about how our products can help your research and therapeutic development.
The FDA's new "plausible mechanism pathway," born from a groundbreaking bespoke CRISPR therapy case, signals a paradigm shift for complex biologics and personalized medicine. While this framework aims to streamline...
Choosing a GMP manufacturing partner is one of the most critical decisions in your clinical development journey. That’s why we created our GMP Open House—a unique opportunity to visit our...
Base editors have promised safer CRISPR therapies, but their clinical translation has faltered owing to their off-target activity. Now, Synthego has partnered with Kactus Biosciences to commercialize AccuBase™ , an...